Orelabrutinib plus R-CHOP in patients with newly diagnosed non-GCB double-expressor DLBCL: A single-arm, phase II study.
A new drug combination achieves nearly 90% complete remission in high-risk lymphoma, though managing side effects remains important.
The study evaluated first-line orelabrutinib plus R-CHOP in high-risk diffuse large B-cell lymphoma. The regimen produced an 89.8% complete response rate and an estimated two-year progression-free survival rate of 82.0%, with grade 3 or higher adverse events in 51.0% of patients.
What the study was
- Study design
- Multicenter single-arm phase II clinical trial
- Population
- 49 patients with newly diagnosed non-GCB double-expressor diffuse large B-cell lymphoma
- Sample size
- 49
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British journal of haematology
Why it surfaced
A prospective phase II study reports encouraging response and survival data, but the single-arm design and small cohort require confirmation
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.